Treats serious bacterial infections caused by susceptible strains of the designated…. ANDA 217519, held by Eugia Pharma. Tobramycin Sulfate.
As of Nov 16, 2026, ANDA 217519 (Tobramycin Sulfate), held by Eugia Pharma, was first approved by FDA on Jun 21, 2023, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Tobramycin is indicated for the treatment of serious bacterial infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Septicemia in the neonate, child, and adult caused by P. aeruginosa, E. coli, and Klebsiella sp. Lower respiratory tract infections caused by P. aeruginosa, Klebsiella sp, Enterobacter sp, Serratia sp, E. coli, and S. aureus (penicillinase and non-penicillinase-producing strains). Serious central-nervous-system infections (meningitis) caused by susceptible organisms. Intra-abdominal infections, including peritonitis, caused by E. coli, Klebsiella sp, and Enterobacter sp.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 21, 2023 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Tobramycin SulfateEQ 1.2GM BASE/VIAL · injectable;injection | Tobramycin Sulfate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters